Illumina, Inc. (NASDAQ:ILMN - Get Free Report) Director Keith Meister sold 98,833 shares of the firm's stock in a transaction on Wednesday, November 11th. The shares were sold at an average price of $216.87, for a total value of $21,433,912.71. Following the transaction, the director directly owned 208,826 shares of the company's stock, valued at $45,288,094.62. This represents a 32.12% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Illumina Stock Down 1.6%
Shares of ILMN stock traded down $3.38 during mid-day trading on Thursday, reaching $209.55. 1,726,386 shares of the company's stock traded hands, compared to its average volume of 2,186,053. The company's 50-day moving average price is $249.39 and its 200-day moving average price is $179.08. The company has a market cap of $31.68 billion, a P/E ratio of 36.07, a P/E/G ratio of 2.92 and a beta of 1.46. The company has a quick ratio of 2.05, a current ratio of 2.63 and a debt-to-equity ratio of 0.57. Illumina, Inc. has a 12 month low of $112.65 and a 12 month high of $309.35.
Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.36 by $0.26. The company had revenue of $1.17 billion during the quarter, compared to analyst estimates of $1.15 billion. Illumina had a net margin of 19.72% and a return on equity of 28.38%. Illumina's quarterly revenue was up 4.2% compared to the same quarter last year. During the same period last year, the business earned $1.34 EPS. On average, equities analysts expect that Illumina, Inc. will post 5.43 earnings per share for the current fiscal year.
Institutional Trading of Illumina
A number of institutional investors and hedge funds have recently bought and sold shares of ILMN. BlackRock Inc. bought a new position in shares of Illumina in the second quarter worth approximately $3,374,423,000. WCM Investment Management LLC grew its holdings in shares of Illumina by 45.5% during the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company's stock valued at $715,579,000 after buying an additional 1,851,848 shares during the last quarter. Primecap Management Co. CA purchased a new stake in shares of Illumina during the second quarter valued at approximately $617,981,000. Ninety One UK Ltd increased its position in shares of Illumina by 37,920.0% during the third quarter. Ninety One UK Ltd now owns 1,359,974 shares of the life sciences company's stock valued at $372,198,000 after acquiring an additional 1,356,397 shares in the last quarter. Finally, Jupiter Topco LLC bought a new stake in shares of Illumina during the second quarter valued at approximately $358,652,000. 89.42% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
A number of brokerages have weighed in on ILMN. Deutsche Bank cut shares of Illumina to a "hold" rating in a report on Wednesday, August 5th. Zacks Research cut Illumina from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 1st. Argus upped their price target on Illumina from $180.00 to $235.00 and gave the stock a "buy" rating in a research note on Thursday, September 3rd. Leerink Partners upped their price target on Illumina from $220.00 to $300.00 and gave the stock an "outperform" rating in a research note on Tuesday, September 29th. Finally, Citigroup raised their price objective on Illumina from $113.00 to $210.00 and gave the company a "sell" rating in a research report on Monday, November 2nd. Ten equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $244.24.
Read Our Latest Report on Illumina
About Illumina
(
Get Free Report)
Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company's technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.